The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy

Viruses. 2024 Feb 16;16(2):302. doi: 10.3390/v16020302.

Abstract

There is great enthusiasm toward the development of novel immunotherapies for the treatment of cancer, and given their roles in immune system regulation, chemokines stand out as promising candidates for use in new cancer therapies. Many previous studies have shown how chemokine signaling pathways could be targeted to halt cancer progression. We and others have revealed that the chemokine CXCL14 promotes antitumor immune responses, suggesting that CXCL14 may be effective for cancer immunotherapy. However, it is still unknown what mechanism governs CXCL14-mediated antitumor activity, how to deliver CXCL14, what dose to apply, and what combinations with existing therapy may boost antitumor immune responses in cancer patients. Here, we provide updates on the role of CXCL14 in cancer progression and discuss the potential development and application of CXCL14 as an immunotherapeutic agent.

Keywords: CXCL14; chemokine; immunotherapy.

Publication types

  • Review

MeSH terms

  • Chemokines*
  • Chemokines, CXC
  • Humans
  • Immunotherapy
  • Neoplasms* / pathology
  • Neoplasms* / therapy

Substances

  • Chemokines
  • Chemokines, CXC
  • CXCL14 protein, human